Skip to main content
Article
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.
J Immunother Cancer
  • Paolo Antonio Ascierto
  • Bernard A Fox, Chiles Research Institute Providence Portland Medical Center
  • Walter Urba, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, 97213, USA.
  • Ana Carrizosa Anderson
  • Michael B Atkins
  • Ernest C Borden
  • Julie Brahmer
  • Lisa H Butterfield
  • Alessandra Cesano
  • Daniel Chen
  • Tanja de Gruijl
  • Robert O Dillman
  • Charles G Drake
  • Leisha A Emens
  • Thomas F Gajewski
  • James L Gulley
  • F Stephen Hodi
  • Patrick Hwu
  • David Kaufman
  • Howard Kaufman
  • Michael Lotze
  • Douglas G McNeel
  • Kim Margolin
  • Francesco Marincola
  • Michael J Mastrangelo
  • Marcela V Maus
  • David R Parkinson
  • Pedro J Romero
  • Paul M Sondel
  • Stefani Spranger
  • Mario Sznol
  • George J Weiner
  • Jon M Wiggington
  • Jeffrey S Weber
Document Type
Article
Publication Date
4-1-2020
Keywords
  • Betacoronavirus,
  • Coronavirus Infections,
  • Drug Approval,
  • Humans,
  • Immunologic Factors,
  • Immunotherapy,
  • Inflammation,
  • Interleukin-6,
  • Neoplasms,
  • Pandemics,
  • Pneumonia, Viral,
  • Receptors, Interleukin-6,
  • 2019-nCoV
Disciplines
Clinical Institute
Cancer
Specialty
Oncology
Specialty
Infectious Diseases
Citation Information
Paolo Antonio Ascierto, Bernard A Fox, Walter Urba, Ana Carrizosa Anderson, et al.. "Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19." J Immunother Cancer (2020)
Available at: http://works.bepress.com/walter-urba/297/